219 related articles for article (PubMed ID: 21600934)
1. Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells.
Masola V; Gambaro G; Tibaldi E; Onisto M; Abaterusso C; Lupo A
Biochim Biophys Acta; 2011 Aug; 1813(8):1475-82. PubMed ID: 21600934
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor.
An XF; Zhou L; Jiang PJ; Yan M; Huang YJ; Zhang SN; Niu YF; Ten SC; Yu JY
Mol Cell Biochem; 2011 Aug; 354(1-2):47-55. PubMed ID: 21461610
[TBL] [Abstract][Full Text] [Related]
3. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells.
Masola V; Gambaro G; Tibaldi E; Brunati AM; Gastaldello A; D'Angelo A; Onisto M; Lupo A
J Biol Chem; 2012 Jan; 287(2):1478-88. PubMed ID: 22102278
[TBL] [Abstract][Full Text] [Related]
4. The receptor for advanced glycation endproducts mediates podocyte heparanase expression through NF-κB signaling pathway.
An X; Zhang L; Yao Q; Li L; Wang B; Zhang J; He M; Zhang J
Mol Cell Endocrinol; 2018 Jul; 470():14-25. PubMed ID: 28478303
[TBL] [Abstract][Full Text] [Related]
5. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition.
Masola V; Onisto M; Zaza G; Lupo A; Gambaro G
J Transl Med; 2012 Oct; 10():213. PubMed ID: 23095131
[TBL] [Abstract][Full Text] [Related]
6. Alteration of endothelial proteoglycan and heparanase gene expression by high glucose, insulin and heparin.
Han J; Hiebert LM
Vascul Pharmacol; 2013; 59(3-4):112-8. PubMed ID: 23939434
[TBL] [Abstract][Full Text] [Related]
7. Properdin Pattern Recognition on Proximal Tubular Cells Is Heparan Sulfate/Syndecan-1 but Not C3b Dependent and Can Be Blocked by Tick Protein Salp20.
Lammerts RGM; Talsma DT; Dam WA; Daha MR; Seelen MAJ; Berger SP; van den Born J
Front Immunol; 2020; 11():1643. PubMed ID: 32849563
[No Abstract] [Full Text] [Related]
8. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.
Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J
Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of advanced glycation end-products on renal tubular cell inflammation.
Tang SC; Chan LY; Leung JC; Cheng AS; Lin M; Lan HY; Lai KN
Nephrology (Carlton); 2011 May; 16(4):417-25. PubMed ID: 21143336
[TBL] [Abstract][Full Text] [Related]
10. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.
Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD
FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281
[TBL] [Abstract][Full Text] [Related]
11. Heparanase regulates levels of syndecan-1 in the nucleus.
Chen L; Sanderson RD
PLoS One; 2009; 4(3):e4947. PubMed ID: 19305494
[TBL] [Abstract][Full Text] [Related]
12. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy.
Wijnhoven TJ; van den Hoven MJ; Ding H; van Kuppevelt TH; van der Vlag J; Berden JH; Prinz RA; Lewis EJ; Schwartz M; Xu X
Diabetologia; 2008 Feb; 51(2):372-82. PubMed ID: 18058084
[TBL] [Abstract][Full Text] [Related]
13. Involvement of human heparanase in the pathogenesis of diabetic nephropathy.
Katz A; Van-Dijk DJ; Aingorn H; Erman A; Davies M; Darmon D; Hurvitz H; Vlodavsky I
Isr Med Assoc J; 2002 Nov; 4(11):996-1002. PubMed ID: 12489489
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.
Maeda S; Matsui T; Takeuchi M; Yamagishi S
Diabetes Metab Res Rev; 2013 Jul; 29(5):406-12. PubMed ID: 23508966
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
16. Targeting of heparanase-modified syndecan-1 by prosecretory mitogen lacritin requires conserved core GAGAL plus heparan and chondroitin sulfate as a novel hybrid binding site that enhances selectivity.
Zhang Y; Wang N; Raab RW; McKown RL; Irwin JA; Kwon I; van Kuppevelt TH; Laurie GW
J Biol Chem; 2013 Apr; 288(17):12090-101. PubMed ID: 23504321
[TBL] [Abstract][Full Text] [Related]
17. Heparanase involvement in physiology and disease.
Nasser NJ
Cell Mol Life Sci; 2008 Jun; 65(11):1706-15. PubMed ID: 18425416
[TBL] [Abstract][Full Text] [Related]
18. Processing advanced glycation end product-modified albumin by the renal proximal tubule and the early pathogenesis of diabetic nephropathy.
Ozdemir AM; Hopfer U; Erhard P; Monnier VM; Weiss MF
Ann N Y Acad Sci; 2005 Jun; 1043():625-36. PubMed ID: 16037286
[TBL] [Abstract][Full Text] [Related]
19. Albumin stimulates renal tubular inflammation through an HSP70-TLR4 axis in mice with early diabetic nephropathy.
Jheng HF; Tsai PJ; Chuang YL; Shen YT; Tai TA; Chen WC; Chou CK; Ho LC; Tang MJ; Lai KT; Sung JM; Tsai YS
Dis Model Mech; 2015 Oct; 8(10):1311-21. PubMed ID: 26398934
[TBL] [Abstract][Full Text] [Related]
20. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients.
Maxhimer JB; Somenek M; Rao G; Pesce CE; Baldwin D; Gattuso P; Schwartz MM; Lewis EJ; Prinz RA; Xu X
Diabetes; 2005 Jul; 54(7):2172-8. PubMed ID: 15983219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
